Sara H Bares1, Laura M Smeaton2, Sarah E Scott3, Beth A Smith3, Catherine Godfrey4, Grace A McComsey3. 1. University of Nebraska Medical Center, Omaha, Nebraska, USA. 2. Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 3. University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 4. Office of the Global AIDS Coordinator, Department of State, Washington, District of Columbia, USA.
Abstract
BACKGROUND: Immune activation persists despite suppressive antiretroviral therapy (ART) and may be affected by sex or body composition. We explored these relationships in a subset of participants who initiated ART in two large randomized trials. METHODS: Purposeful sampling selected participants who achieved virologic suppression on ART and either maintained weight within ± 0.5 kg/m2 or gained 2.6-6.4 kg/m2 from baseline to 96 weeks. We measured 7 markers of inflammation and immune activation at weeks 0 and 96. Multivariable linear regression explored associations of weight gain, sex, and pre-ART BMI with pre-ART and changes in biomarker concentrations. RESULTS: 340 participants were selected; median pre-ART age 42 years, CD4+ cell count 273 cells/mm3, HIV-1 RNA 4.7 log10 copies/mL; 49% were women, 33% white, 42% black, and 24% Hispanic. Among participants with a normal pre-ART BMI, higher pre-ART levels of IL-6, sTNF-RI and RII, CXCL-10, sCD163 and hsCRP were associated with weight gain. Association of weight gain with week 96 changes of these biomarkers differed by sex; women who gained weight had smaller declines in most measured biomarkers compared to men who gained. CONCLUSIONS: Among women, weight gain is associated with attenuated decline in several immune activation markers following ART initiation. Clinical Trials Registration. NCT00811954 and NCT00811954.
BACKGROUND: Immune activation persists despite suppressive antiretroviral therapy (ART) and may be affected by sex or body composition. We explored these relationships in a subset of participants who initiated ART in two large randomized trials. METHODS: Purposeful sampling selected participants who achieved virologic suppression on ART and either maintained weight within ± 0.5 kg/m2 or gained 2.6-6.4 kg/m2 from baseline to 96 weeks. We measured 7 markers of inflammation and immune activation at weeks 0 and 96. Multivariable linear regression explored associations of weight gain, sex, and pre-ART BMI with pre-ART and changes in biomarker concentrations. RESULTS: 340 participants were selected; median pre-ART age 42 years, CD4+ cell count 273 cells/mm3, HIV-1 RNA 4.7 log10 copies/mL; 49% were women, 33% white, 42% black, and 24% Hispanic. Among participants with a normal pre-ART BMI, higher pre-ART levels of IL-6, sTNF-RI and RII, CXCL-10, sCD163 and hsCRP were associated with weight gain. Association of weight gain with week 96 changes of these biomarkers differed by sex; women who gained weight had smaller declines in most measured biomarkers compared to men who gained. CONCLUSIONS: Among women, weight gain is associated with attenuated decline in several immune activation markers following ART initiation. Clinical Trials Registration. NCT00811954 and NCT00811954.
Authors: Eduardo Ticona; Marta E Bull; Jaime Soria; Kenneth Tapia; Jillian Legard; Sheila M Styrchak; Corey Williams; Caroline Mitchell; Alberto La Rosa; Alberto L A Rosa; Robert W Coombs; Lisa M Frenkel Journal: AIDS Date: 2015-08-24 Impact factor: 4.177
Authors: John R Koethe; Cathy A Jenkins; Bryan Lau; Bryan E Shepherd; Amy C Justice; Janet P Tate; Kate Buchacz; Sonia Napravnik; Angel M Mayor; Michael A Horberg; Aaron J Blashill; Amanda Willig; C William Wester; Michael J Silverberg; John Gill; Jennifer E Thorne; Marina Klein; Joseph J Eron; Mari M Kitahata; Timothy R Sterling; Richard D Moore Journal: AIDS Res Hum Retroviruses Date: 2015-09-09 Impact factor: 2.205
Authors: Nancy Crum-Cianflone; Mollie Poehlman Roediger; Lynn Eberly; Maryam Headd; Vincent Marconi; Anuradha Ganesan; Amy Weintrob; R Vincent Barthel; Susan Fraser; Brian K Agan Journal: PLoS One Date: 2010-04-09 Impact factor: 3.240
Authors: R S De Pablo-Bernal; E Ruiz-Mateos; I Rosado; B Dominguez-Molina; A I Alvarez-Ríos; A Carrillo-Vico; R De La Rosa; J Delgado; M A Muñoz-Fernández; M Leal; S Ferrando-Martínez Journal: J Antimicrob Chemother Date: 2014-07-09 Impact factor: 5.790
Authors: Jyoti S Mathad; Nikhil Gupte; Ashwin Balagopal; David Asmuth; James Hakim; Breno Santos; Cynthia Riviere; Mina Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Noluthando Mwelase; Jyoti Pawar; Sima Berendes; Nagalingeswaran Kumarasamy; Bruno B Andrade; Thomas B Campbell; Judith S Currier; Susan E Cohn; Amita Gupta Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Paul E Sax; Kristine M Erlandson; Jordan E Lake; Grace A Mccomsey; Chloe Orkin; Stefan Esser; Todd T Brown; Jürgen K Rockstroh; Xuelian Wei; Christoph C Carter; Lijie Zhong; Diana M Brainard; Kathleen Melbourne; Moupali Das; Hans-Jürgen Stellbrink; Frank A Post; Laura Waters; John R Koethe Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079